Lexicon Pharmaceuticals, Inc. LXRX
1.86 USD +0.04 (+2.20%)
At closeNov 10, 2026, 6:34 PM EST
1.85 -0.01 -0.52%
After hours · Nov 10, 6:34 PM ET
1.80 Day range 1.97
1.10 52-week range 2.68
- YTD
- +61.74%
- 1 year
- +30.99%
News
benzinga.com Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.4 Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $3.1 to $3.4.
benzinga.com Lexicon Pharma Presents New Data Highlighting Cardiovascular Effects Of Dual SGLT1/2 Inhibitor, Sotagliflozin, At AHA Scientific Sessions 2026 -- In a randomized crossover study, sotagliflozin significantly reduced ex vivo thrombus formation from baseline under both arterial and venous flow conditions ---- Study in living human heart tissue…
globenewswire.com New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy -- In a randomized crossover study, sotagliflozin significantly reduced ex vivo thrombus formation from baseline under both arterial and venous flow conditions -- -- Study in living human heart…
seekingalpha.com Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2026 Earnings Call Transcript Lexicon Pharmaceuticals, Inc. ( LXRX ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Lisa DeFrancesco - Senior Vice President of Investor Relations & Corporate…
marketbeat.com What Lexicon Pharmaceuticals (LXRX) Said on Its Q3 Earnings Call Lexicon Pharmaceuticals NASDAQ: LXRX expects two key milestones in the first quarter of 2027: results from a pivotal heart disease trial and a resubmission of its application for a type 1 diabetes…
zacks.com Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue Estimates Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.04 per share a year ago.
benzinga.com Lexicon Pharmaceuticals Q3 2026 Earnings Call Transcript Lexicon Pharmaceuticals (NASDAQ:LXRX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
benzinga.com Lexicon Pharmaceuticals Q3 EPS $(0.03) Beats $(0.06) Estimate, Sales $11.250M Beat $4.142M Estimate Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 25 percent increase over losses of…
globenewswire.com Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical…
globenewswire.com Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its…
benzinga.com Lexicon Pharmaceuticals Issues Update On Baseline Characteristics Of Patients Randomized Into Its Ongoing Pivotal Phase 3 SONATA-HCM Clinical Trial Evaluating Sotagliflozin In Patients With Symptomatic Hypertrophic Cardiomyopathy; Patient Enrollment Profile Of SONATA-HCM Is Consistent With Study’s Inclusive Design Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update on the baseline characteristics of the patients randomized into the ongoing…
globenewswire.com Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy -- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study…
benzinga.com Lexicon Highlights Preclinical Studies Showing Biological Effects Of Sotagliflozin In Hypertrophic Cardiomyopathy And Thrombotic Disease Pathways -- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy ---- Second preclinical study shows inhibitory effects of…
globenewswire.com Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular Disease -- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of…
defenseworld.net Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Falls 5.2% – Here’s What Happened Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report)'s share price fell 5.2% during trading on Monday. The company traded as low as $1.72 and last traded at $1.7250. Approximately 1,402,888…
benzinga.com Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript Lexicon Pharmaceuticals (NASDAQ:LXRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs.…
seekingalpha.com Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. LXRX anticipates NDA resubmission for ZYNQUISTA in T1D by Q4 2026, contingent on STENO1…
fool.com Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today He feels it's a clear buy at the current price. In his view, sotagliflozin has excellent potential to win FDA approval for a new indication.
defenseworld.net Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of “Hold” from Brokerages Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report) have received an average rating of "Hold" from the five research firms that are covering the company, MarketBeat Ratings…
benzinga.com This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).- benzinga.com Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8 Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Overweight rating and announces Price Target of $8.
defenseworld.net Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data Lexicon Pharmaceuticals (NASDAQ: LXRX) said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first…
marketbeat.com Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first…
benzinga.com Beta Bionics, J.B. Hunt Transport And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures rose, but Beta Bionics fell 7.1% after pricing a stock offering; several other stocks also declined in premarket trading.- benzinga.com Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.
seekingalpha.com Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
globenewswire.com Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences…
globenewswire.com Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure
globenewswire.com Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851 LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
seekingalpha.com Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotagliflozin, and the shares have been strong since my last update. Sotagliflozin, targeting HCM and T1D,…
benzinga.com Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 800 percent decrease over earnings…- benzinga.com Lexicon Pharmaceuticals Completes Randomization Of Patients In Its Pivotal Phase 3 'Sotagliflozin In Patients With Symptomatic Obstructive And Non-Obstructive Hypertrophic Cardiomyopathy' Clinical Trial The study substantially exceeded its enrollment target of 500 patients across more than 130 sites in 20 countries. The primary efficacy endpoint will assess improvement in symptoms for the entire…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1 Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $2.3 to $3.1.- benzinga.com Lexicon Pharmaceuticals Q1 Sales $1.090M Miss $9.380M Estimate Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly sales of $1.090 million which missed the analyst consensus estimate of $9.380 million by 88.38 percent. This is a 13.63 percent decrease over…
- benzinga.com Lexicon Pharmaceuticals To Present Data From Its PROGRESS Phase 2b Trial Of Pilavapadin In Diabetic Peripheral Neuropathic Pain To Support Selection Of Pilavapadin 10 Mg As Optimal Dose For Phase 3 Development Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) supporting the selection of…
benzinga.com Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market. Other stocks lower in pre-market trading.
benzinga.com HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $6 price target.- benzinga.com Lexicon Pharmaceuticals And Novo Nordisk Initiate Phase 1 Study With LX9851, An Oral Non-incretin Development Candidate, For Obesity And Associated Metabolic Disorders In March 2025, Lexicon signed an exclusive license agreement with Novo Nordisk for LX9851 in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtained an…
benzinga.com Earnings Scheduled For March 5, 2026 
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Gold Tumbles Over 6%; Apple Posts Upbeat Earnings - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Progress Software Posts Upbeat Q4 Earnings, Joins ServisFirst Bancshares, Zura Bio And Other Big Stocks Moving Higher On Wednesday 
benzinga.com Tilray Brands, SuperX AI Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1…- benzinga.com Earnings Scheduled For August 6, 2025